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Robotic-assisted laparoscopic extended pelvic lymph node
dissection for prostate cancer: surgical technique and experience
with the first 99 cases
Abstract
BACKGROUND: To date, there is still a paucity of data in the literature on robotic-assisted
laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer.
OBJECTIVE: To assess the technical feasibility of RALEPLND and to present our surgical technique.
DESIGN, SETTING, AND PARTICIPANTS: From April 2006 to March 2008, we performed
RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for
RALEPLND were a prostate-specific antigen (PSA) >/=10 ng/ml or a preoperative Gleason score >/=7.
The data were evaluated retrospectively. SURGICAL PROCEDURE: The transperitoneal approach was
used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were
placed in a more cephalad position than in patients undergoing radical prostatectomy without
RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac
vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed
on both sides. MEASUREMENTS: The total lymph node yield, the frequency of lymph node
metastases, and the complication rate. RESULTS AND LIMITATIONS: The median patient age was 64
yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median
number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node
metastasis. Complications occurred in seven patients (7%). CONCLUSIONS: RALEPLND is feasible,
and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach
in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node
dissection.
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Abstract 
Background: To date there is still a paucity of data in the literature on robotic-assisted 
laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate 
cancer.  
Objective: To assess the technical feasibility of RALEPLND and to present our surgical 
technique. 
Design, Setting and Participants: From April 2006 to March 2008 we performed 
RALEPLND in 99 patients prior to robotic assisted laparoscopic radical prostatectomy. 
Indications for RALEPLND were a prostate-specific antigen (PSA) ≥ 10 ng/ml or a 
preoperative Gleason score ≥ 7. The data were evaluated retrospectively. 
Surgical procedure: The transperitoneal approach was used in all cases. In order to gain 
optimal access to the common iliac bifurcation the five trocars were placed in a more 
cephalad position than in patients undergoing radical prostatectomy without RALEPLND. 
After identification of important landmarks the lymphatics covering the external iliac vein, 
the obturator lymphatic packet, and the lymphatic’s overlying the internal iliac artery were 
removed on both sides. 
Measurements: The total lymph node yield, the frequency of lymph node metastases and the 
complication rate. 
Results and limitations The median patient age was 64 years (range 45 to 78). The median 
preoperative PSA level was 7.7 ng/ml (range 1.5 to 84.6). The median number of lymph 
nodes harvested was 19 (range 8 to 53). In 16 patients (16%) we found lymph node 
metastasis. Complications occurred in 7 patients (7%).  
Conclusion: RALEPLND is feasible and its lymph node yield is well in the range of open 
series. The robotic assisted laparoscopic approach in itself does not seem to limit a surgeon’s 
ability to perform a complete extended pelvic lymph node dissection. 
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Introduction 
Robotic assisted laparoscopic radical prostatectomy is an increasingly popular procedure 
throughout Europe and the United States. This is reflected by a rapidly increasing number of 
publications reporting various refinements of technique as well as functional outcomes and 
early oncological results [1-3]. Yet, ever since the initial reports by Guilloneau et al,  robotic 
lymph node dissection in patients undergoing radical prostatectomy did not receive much 
attention in the robotic urological community [4]. This is in contrast to the ongoing debate 
concerning the extent of and the indication for a lymph node dissection in patients undergoing 
radical prostatectomy for prostate cancer [5-9]. There’s much confusion among different 
authors and centres concerning the terminology and the boundaries of the lymph node 
dissection [10,11]. However, increasing evidence supports an extended lymph node dissection 
in patients with prostate cancer once the PSA level is greater than 10 ng/ml or the Gleason 
score totals 7 or more. Likewise, recent data suggest renouncing a lymph node excision in low 
risk patients [5,6,12]. Data on conventional laparoscopic pelvic lymph node dissection in 
patients with prostate cancer are widely available [13-15]. Yet, none of the recently published 
studies included experience with robotic-assisted laparoscopic pelvic lymph node dissection. 
Thus, to date there is still a paucity of data in the literature on robotic-assisted laparoscopic 
extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer.  The 
aim of this study was to assess the technical feasibility and to analyze our experience with 
RALEPLND. In addition, our surgical technique of RALEPLND is presented in detail in the 
complementary video. 
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Patients and methods 
Patient population 
From April 2006 to March 2008 234 men underwent robotic-assisted laparoscopic radical 
prostatectomy in our department. In 99 of these patients we performed RALEPLND prior to 
robotic-assisted laparoscopic radical prostatectomy (RALRP). In two patients referred to our 
department for staging purposes only, we performed only RALEPLND without RALRP: The 
reasons were the bulky lymph node packets subsequently tested positive in the frozen section 
analysis in one case, while the second patient refused radical prostatectomy and opted for 
radiotherapy.  
Indications for RALEPLND were either a PSA ≥ 10 ng/ml or a preoperative Gleason score ≥ 
7. Patients with a clinical T3 tumor who opted for radical prostatectomy were included as 
well. Preoperatively, 79 patients (80%) underwent staging examinations with computed 
tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis and/or 
bone scan. All preoperative diagnostics were negative for metastasis. Further patients’ 
characteristics are shown in table 1. Low-dose heparin was applied into the upper arm in order 
to prevent deep vein thrombosis. 
Pathologic work-up to detect lymph nodes as well as lymph node metastases included direct 
visualization and palpation, and standard hematoxylin-eosin staining, respectively.  
 
Statistical methods 
Clinical information and pathological data were evaluated retrospectively with descriptive 
statistics. 
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Description of the surgical technique 
The patients were placed in a 20-30° Trendelenburg position. The transperitoneal route was 
chosen in all patients undergoing RALEPLND on account of excellent working space. Using 
a three-arm Da Vinci® robotic system we routinely placed 5 trocars. All of these trocars were 
placed in a more cephalad position than in patients undergoing RALRP without RALEPLND 
in order to gain better access to the common iliac bifurcation (Fig. 1). The trocar for the 
robotic camera was placed in the midline sub-or supra-umbilical depending on how tall the 
patient was. Two 8 mm pararectus trocars for the robotic working instruments were placed on 
the left and right side slightly lower than the camera trocar. We placed two additional trocars 
that were used by a single assistant, usually one 5 mm trocar between the camera and right 
working trocar and a 12 mm trocar medial and cranial to the right anterior superior crest.  In 
patients with a narrow pelvis we placed the trocar for the robotic camera 3-4 cm to the left of 
the umbilicus in order to gain additional space for the assistant trocars. 
 
Identification of landmarks and peritoneal incision 
As with any other procedure the RALEPLND has to proceed from one landmark to the next. 
Therefore, in the manuscript and especially in the DVD we highlight the specific landmarks 
that should be identified during the course of the dissection. 
We use the boundaries of the lymph node dissection according to Bader et al and their recent 
modification by Mattei et al., proposing to include the common iliac region up to the ureteric 
crossing [5, 9, 13, 16, 17]. Special attention is paid to the careful dissection of the tissue 
medially to the internal iliac artery. 
After mobilizing the right ascending and left descending as well as sigmoid colon if indicated, 
the lymphadenectomy is initiated. Of major importance is the identification of several 
important landmarks: Identification of the median and medial umbilical folds and the 
pulsation of the external iliac artery. Frequently, the vas deferens and the ureter are already 
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visible beneath the peritoneum. After identification of these landmarks the incision of the 
peritoneum starts laterally to the medial umbilical fold longitudinally along the external iliac 
vessels (Fig 2). Distally, the incision and dissection is carried out until the pubic bone is 
clearly identified (Fig. 3). Proximally, the peritoneal incision proceeds up to the crossing of 
the ureter over the common iliac artery (Fig 4). The vas deferens (Fig. 3) is cauterized and 
divided. After these steps, the cephalad and caudal boundaries of the lymph node dissection 
are defined.  
 
Dissection of the external iliac lymphatic packet 
The dissection of the external iliac packet starts distally with the division of the adventitia 
overlying the external iliac vein (Fig. 5). In doing so, the lymphatic tissue covering the 
external iliac artery remains untouched. The distal end of the packet is divided and secured 
with hemolock clips. The lymphatic packet is grasped and retracted in a cephalad and medial 
direction which allows for blunt and sharp dissection of the packet from the underlying vein. 
The dissection proceeds until the upper boundary, i.e. the ureter, is reached. 
 
Dissection of the obturator lymphatic packet 
The second region to be cleared from its lymphatic tissue is the obturator fossa. The most 
crucial step in this region is the identification of the obturator nerve (Fig. 6). Great care 
should be paid to avoid any injury to this nerve. The dissection is initiated at the angle 
between the external iliac vein and the pubic bone. Only after clear identification of the 
obturator nerve, the distal end of the packet is secured with hemolock clips and divided. The 
packet is dissected beneath the external iliac vein and proceeds to the pelvic side wall being 
the lateral boundary of the dissection. The proximal attachments of the packet are dissected 
using a combination of sharp and blunt dissection, always paying close attention to avoid any 
sharp, blunt or thermal injury to the nerve. Alternatively, it is possible to identify the obturator 
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nerve early in the course of the obturator dissection. When separating the external iliac artery 
and vein just distal to the bifurcation of the common iliac artery the obturator nerve becomes 
visible in its proximal course (Fig. 7). However, we perform this maneuver in any case at the 
end of the dissection of the obturator fossa to ascertain that all lymphatic tissue has been 
cleared out of this region. 
 
Dissection of the internal iliac (hypogastric) lymphatic packet 
The internal iliac artery is usually identified after the initial peritoneal incision. At the latest 
the bifurcation of the common iliac artery should be visible after the completion of the 
dissection of the external packet. Alternatively, following the medial umbilical ligament down 
to the pelvic floor will lead to the internal iliac artery. The fibrofatty tissue containing the 
lymphatics overlying the internal iliac artery and its obturator and especially the medial 
vesical branches is completely removed (Fig. 8). 
The lymph node dissection is completed only after a careful inspection for bleeding and 
thoroughness of the dissection has been carried out. The lymph node packets from each 
region are removed and sent to the pathologist separately. Only packets that are too big to be 
removed through the 12 mm trocar are retrieved within a specimen bag. We have renounced 
to place drains. 
 
 
 
Results  
RALEPLND was completed successfully in all 99 patients. None of the cases had to be 
converted to open surgery. The median time to complete the lymph node dissection was 51 
minutes (range 29 - 81). The median number of lymph nodes removed was 19 (mean 19.4, 
range 8 to 53). The left and right side accounted for an equal number of lymph nodes 
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retrieved. In 16 patients (16%) lymph node metastasis was detected (Table 2). In lymph node-
positive patients the median PSA level was 12.25 ng/ml (range 6.3 to 56). The number of 
metastatic lymph nodes with regard to pathologic Gleason score and pathologic T stage are 
shown in tables 2 and 3. In 9 patients (56%) only one lymph node was found to harbour a 
metastasis. Table 4 shows the distribution of the removed lymph nodes and lymph node 
metastases. Complications presumably associated with the RALEPLND occurred in 7 patients 
(7%). We noted 1 lymphatic fistula at a port site, which closed spontaneously. Lymphedema 
was observed in two patients: In one patient a bilateral lymphedema of the lower leg resolved 
after physical therapy with supportive lymphatic drainage. The other patient showed 
persistent unilateral lymphedema in the follow-up after 3 months. In two patients a 
symptomatic lymphocele was treated conservatively. In two patients a lymphocele was 
successfully drained percutaneously. The overall median blood loss for RALRP including the 
extended lymph node dissection was 500 ml and two patients received blood transfusions (2 
units per patient).  However, the transfusions were not related to (excessive) bleeding 
associated with RALEPLND but rather to bleeding during RALRP. No deep vein thrombosis 
was recorded. In one patient a port site infection was successfully treated with antibiotics. 
 
 9
Discussion 
With respect to our results with a median lymph node yield of 19 and the applied dissection 
template and surgical technique, we were able to demonstrate the feasibility of a sound 
robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND). Much 
has been written about dissection templates, indications and oncological outcome for 
extended and limited lymph node dissection in patients with prostate cancer [5-7, 9, 12, 18]. 
The lack of standardization in the terminology and the definitions of anatomic dissection 
boundaries make a comparison between published data difficult [6]. We chose a dissection 
template that was well defined by others, not only in order to facilitate comparison of the 
results, but also because good evidence is provided in the literature to support this dissection 
template [9, 16]. One important advantage of this dissection template is the preservation of 
the lymphatics overlying the external iliac artery thus decreasing the risk of lymphedema of 
the lower extremities [5, 15]. In this perspective a median lymph node yield of 19 is well in 
the range of the published data of the respected open series [5, 9, 12, 19]. Additionally, this 
yield is in line with the frequently quoted study by Weingärtner et al on cadavers considering 
a lymph node yield of 20 to be an accurate staging procedure [20]. 
The frequency of the detected lymph node metastasis is not only related to the dissection 
template but also to the study population. Therefore, it depends on the indication for the 
lymph node dissection. Unfortunately, several authors use the terms low, intermediate and 
high risk in different ways, which again makes comparison between results difficult [5, 13, 
15]. Basically, we chose to perform an extended lymph node dissection in intermediate and 
high-risk patients according to the definition of D’Amico et al [21]. We found lymph node 
metastases in 16% of our intermediate and high-risk patients. This frequency of detected 
metastases is similar to other recently reported results [13, 19]. Of note, 25% of all metastatic 
lymph nodes were detected in the area around the internal iliac artery. Although this 
frequency is lower than in other reports, these findings support the idea to include the area 
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around the internal iliac artery into the dissection template for extended pelvic lymph node 
dissection as pointed out by other authors [9, 22]. 
Typically, lymphocele formation is the most frequent complication associated with lymph 
node dissection [23]. In our series we noted symptomatic lymphocele formation in 5 patients. 
However, only in two patients lymphoceles needed to be drained percutaneously. It is of note 
that the frequency of these complications was similar to other reports although we placed no 
drains [5, 9, 13, 15]. Therefore, based on our results we question the need to place two drains 
in patients undergoing extended lymph node dissection, at least when choosing a robotic-
assisted transperitoneal approach. Pelvic drain placement not only has been discussed to 
prevent lymphocele formation but also to prevent urinoma formation and postoperative 
hematoma. Two recently published articles addressed the issue of pelvic drainage after 
prostatectomy, concluding that pelvic drainage can be omitted in up to 90% of robotic 
assisted prostatectomies [24, 25]. In accordance with these two recently published articles we 
assessed the integrity of the vesico-urethral anastomosis intraoperatively in all patients of our 
series with a bladder filling with 50 - 100 ml saline. As no leakage was observed we 
renounced to place a pelvic drain. No other serious complications associated with 
RALEPLND were observed.  
Another technical refinement is the separation of the external iliac artery and vein. The 
robotic-assisted dissection of lymphatic tissue at the proximal course of the obturator nerve is 
difficult due to impaired vision during retrograde dissection. Separation of the external iliac 
vessels allows for antegrade dissection and proper clearance of this region (Fig. 6). We 
routinely commence the procedure with the RALEPLND. With the robotic approach, tension 
on the medial umbilical ligament to ease dissection of the hypogastric region is no longer 
possible, once the bladder has been mobilized (“dropped”) completely.  Tension to the medial 
umbilical ligament is of importance to dissect the lymphatic tissue in the hypogastric region. 
Therefore, we prefer to perform the RALEPLND before RALRP. 
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Several limitations deserve mention. An important caveat is not using a specimen bag to 
retrieve the lymph node packets as this could pose a risk for port site recurrence. Although a 
port site recurrence after laparoscopic radical prostatectomy in general is exceedingly rare in 
patients with intermediate and high risk features, it might be increased [26, 27]. Therefore, we 
strongly recommend using specimen bags. Outside of study protocols a single retrieval bag 
might suffice, as an assessment of lymph node metastases by different sites is not indicated. 
Another point is that certainly a learning curve is included in our results. All four console 
surgeons are familiar either with open extended pelvic lymph node dissection or laparoscopic 
lymph node dissection in patients with prostate cancer. However, two out of four surgeons 
were robotic novices and thus had no experience in robotic lymph node dissection. This is 
possibly reflected in the median lymph node yield of the first 50 patients being 16 compared 
to the second 49 patients where a median of 21 nodes were removed. Another limitation is the 
relatively small number of patients. However, the main purpose of this analysis was to assess 
the technical feasibility and the nodal yield of the intervention, but not to redefine indications 
and the extent of pelvic lymph node dissection in patients with prostate cancer.  
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Conclusion 
In our experience RALEPLND is feasible and its lymph node yield is well in the range of 
open series. The robotic assisted laparoscopic approach in and of itself does not seem to 
preclude a complete extended pelvic lymph node dissection. 
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Tables 
Table 1 
Patient characteristics 
No of patients 99 
Median age, years (range) 64 (45 - 78) 
BMI (range) 26.4 (19.8 - 34.3) 
Median preoperative PSA, ng/ml (range) 7.7 (1.5 - 84.6) 
Preoperative Gleason score, No (%) *  
             5   2 (2%) 
             6 18 (18%) 
             7 64 (65%) 
             8   8 (8%) 
             9   5 (5%) 
           10   0 
Clinical T Stage, No (%)  
           cT1 66 (67%) 
           cT2 27 (27%) 
           cT3 6 (6%) 
* Gleason score not available for 2 patient  
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Table 2 
Number of metastases according to pathologic Gleason score 
Pathologic Gleason score * Number of patients, No 
Number of patients with 
metastases, No (%) 
Total 95 16 (16%)° 
             5 0 0 
             6 5 0 
             7 69 5 (7%) 
             8 11 6 (55%) 
             9 10 4 (40%) 
           10 0 0 
No Gleason score determined 4 1 
* Gleason score not available for 4 patients. In 2 patients because no prostatectomy was performed and in 2 
patients because the patients received neoadjuvant androgen deprivation therapy by referring urologists.  
° Percentage based on all 99 patients undergoing RALEPLND. 
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Table 3 
Number of metastases according to pathologic T stage  
Pathologic T stage * Number of patients, No 
Number of patients with 
metastases, No (%) 
Total 97 16 (16%)° 
         pT2a 13 0 (0%) 
         pT2b 1 1 (100%) 
         pT2c 56 5 (9%) 
         pT2a-c 70 6 (9%) 
         pT3a 15 4 (27%) 
         pT3b 12 6 (50%) 
         pT3a/b 27 10  (37%) 
         pT4 0 0 
* Pathologic T stage not available for 2 patients because no prostatectomy was performed.  
° Percentage based on all 99 patients undergoing RALEPLND 
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Table 4 
Number of lymph nodes and metastases according to anatomic region 
Anatomic region 
Total number lymph 
nodes 
Metastatic lymph 
nodes 
Exclusively 
metastatic in this 
region 
Internal iliac 
(hypogastric)  
329 5 (1.5%) 1 
External iliac  597 6 (1.0%) 3 
Obturator fossa 993 9 (0.9%) 5 
Total 1919 20 (1.0%)  
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Figures 
 
Figure 1 
A 12 mm trocar for the camera is placed to the left of the umbilicus (a). The 8 mm robotic 
trocars are placed pararectal on the right side and in a more lateral position on the left side (b, 
c). One assistant trocar (12 mm) is placed in a medial and cranial position of the anterior 
superior iliac spine (d). This trocar set-up provides additional working space for the second 
assistant trocar (5mm) between the camera and right robotic trocar(e). 
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Figure 2 
Primary incision line and identification of landmarks (right side) 
 
 
 
Figure 3 
Identification of the pubic bone after dissection of the Retzius space (right side). 
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Figure 4 
Identification of the right ureter and internal iliac artery, thus defining the proximal dissection 
boundary. 
 
 
 
Figure 5 
Starting point for the dissection of the lymphatics overlying the external iliac vein by dividing 
the adventitia overlying the external iliac vein. 
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Figure 6 
Starting point for the dissection of the obturator lymphatic packet at the angle between the 
pubic bone and external iliac vein. 
 
 
 
Figure 7 
Identification of the obturator nerve at its proximal course after separating the external iliac 
artery and vein. 
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Figure 8 
Overview after completion of the extended pelvic lymph node dissection. 
 
 
 
 
 
 
 
 
